Observation on the clinical effect and anti-angiogenesis effect in acute leukemia after treatment by thalidomide

Objective To observe the clinical effect and the influence of the level of plasma vascular endothelial growth factor(VEGF),vascular endothelial growth factor receptor(VEGFR),basic fibroblast growth factor(bFGF) and bone marrow microvascular density(MVD) in acute leukemia after treatment by thalidomide combined with chemotherapy.Methods 36 cases of acute leukemia patients were randomly divided into experimental group and control group by 18 cases each.Each group was treated with chemotherapy meanwhile in the experimental group additional thalidomide 100 mg/day were taken orally.Before treatment and 8 weeks after treatment,plasma were collected for the detection of VEGF,VEGFR,bFGF and MVD by double antibody sandwich enzyme-linked immunosorbent assay(ELISA).Results The ratio of effective were 88.9%(16/18),77.8%(14/18) respectively in experimental group and control group,the difference was statistically significant(P 0.05).The difference of the levels of plasma VEGF、VEGFR and MVD in experimental group and control group after treatment[(211.74 ± 36.72)pg/mL vs.(288.02 ± 31.77)pg/mL;[(1 359.71 ± 390.24)pg/mL vs.(1 753.89 ± 337.04)pg/mL;(8.30 ± 4.57)n/HP vs.(14.78 ± 2.76)n/HP] was statistically significant(all P 0.05),while[bFGF(2.09 ± 0.17)ng/mL vs.(2.11 ± 0.31)ng/mL]was not statistically significant(P 0.05).Conclusion Thalidomide combined with chemotherapy can improve the remission rate in acute leukemia,its mechanism may be conduced through inhibiting the plasma levels of VEGF and VEGFR to decrease MVD,then take effect on anti-leukemia.